Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 89 clinical trials
featured
A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with MTX in participants with moderately to severely active RA who have an inadequate response to MTX.

A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with MTX in participants with moderately to severely active RA who have an inadequate response to MTX.  

tofacitinib
  • 55 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During …

programmed cell death 1 ligand 1
carcinoma
measurable disease
unresectable renal cell carcinoma
karnofsky performance status
  • 0 views
  • 23 Nov, 2020
  • 3 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a

hu3f8
colony stimulating factor
monoclonal antibodies
high-risk neuroblastoma
bone marrow procedure
  • 156 views
  • 13 Jan, 2020
  • 24 locations
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer

This is a phase I study looking at the safety of cancer peptides combined with adjuvant and GM-CSF in subjects with estrogen receptor (ESR) positive breast cancer. The primary objective of the

estrogen
immunostimulant
estrogen receptor
ESR1
  • 0 views
  • 14 Sep, 2020
  • 1 location
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients

Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg

liver failure
hepatitis b e antigen
entecavir
interferon
chronic hepatitis
  • 5 views
  • 08 Nov, 2020
  • 1 location
Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma

The aim of this research project is to assess the efficacy and toxicity of hypofractionated carbon-ion radiotherapy with concurrent granulocyte-macrophage colony-stimulating factor for the treatment of hepatocellular carcinoma

cancer
liver cancer
liver disease
metastasis
alpha fetoprotein
  • 6 views
  • 08 Nov, 2020
  • 1 location
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB IIC and III Melanoma Patients

Randomized, open, Phase II-III study, comparative between treatment with CSF-470 vaccine , allogeneic, irradiated with BCG and molgramostin (rHuGM-CSF) as adjuvants and interferon alfa 2b (IFN-alpha2b) treatment , in stages IIB, IIC o III (AJCC) post-surgery cutaneous melanoma patients. This study has been approved by ANMAT ( Administracin Nacional de …

malignant melanoma of skin
immunologic adjuvant
melanoma stage
direct bilirubin
ct scan
  • 56 views
  • 08 Nov, 2020
  • 1 location
A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

included. Study design: Randomized controlled trial Study period: August 2019 to December 2021. Sample size: Assuming that the response rate is 90% with GM-CSF and 60% without GM-CSF after day 5

  • 0 views
  • 25 Feb, 2020
  • 1 location
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

The purpose of this study is to test the combination of Ipilimumab and GM-CSF. Both ipilimumab and GM-CSF are intended to work with the body's own immune system to attack melanoma cells in the

  • 26 views
  • 08 Nov, 2020
  • 1 location
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin

measurable disease
estrogen
monoclonal antibodies
breast cancer
estrogen receptor
  • 0 views
  • 23 Sep, 2020